FDA says ESAs need panel review for chronic kidney disease
This article was originally published in Scrip
Executive Summary
US FDA officials have said in an article published in the New England Journal of Medicine that a public advisory committee meeting will likely be convened this year to re-evaluate the use of erythropoiesis-stimulating agents (ESAs) for the treatment of chronic kidney disease.